Clinical Trials

Small Cell Lung Carcinoma

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

600 enrolled

Endometrial Neoplasms

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

466 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

574 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07419295 2026-02-19

TroFuse-031

590 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07418749 2026-02-18

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Uterine Cervical Neoplasms

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

480 enrolled

Squamous Non-small Cell Lung Cancer

NCT07298772 2025-12-23

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

198 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06867562 2025-03-10

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

166 enrolled

Platinum-Resistant Primary Peritoneal Carcinoma

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

430 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

380 enrolled

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

120 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06620029 2024-10-01

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

27 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

642 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05794659 2023-07-20

Cornerstone4

98 enrolled

Advanced Ovarian Cancer

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)